BioNTech SE (F:22UA) — Market Cap & Net Worth
Market Cap & Net Worth: BioNTech SE (22UA)
BioNTech SE (F:22UA) has a market capitalization of $23.24 Billion (€19.88 Billion) as of May 2, 2026. Listed on the F stock exchange, this Germany-based company holds position #1104 globally and #253 in its home market, demonstrating a -5.92% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioNTech SE's stock price €88.25 by its total outstanding shares 250930737 (250.93 Million). Analyse cash efficiency ratio of BioNTech SE to see how efficiently the company converts income to cash.
BioNTech SE Market Cap History: 2019 to 2026
BioNTech SE's market capitalization history from 2019 to 2026. Data shows growth from $8.95 Billion to $25.89 Billion (33.93% CAGR).
BioNTech SE Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioNTech SE's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
11.59x
BioNTech SE's market cap is 11.59 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $8.95 Billion | $108.59 Million | -$179.06 Million | 82.40x | N/A |
| 2020 | $21.30 Billion | $482.32 Million | $15.20 Million | 44.16x | 1401.39x |
| 2021 | $62.78 Billion | $18.98 Billion | $10.29 Billion | 3.31x | 6.10x |
| 2022 | $42.26 Billion | $17.31 Billion | $9.43 Billion | 2.44x | 4.48x |
| 2023 | $27.87 Billion | $3.82 Billion | $930.30 Million | 7.30x | 29.96x |
| 2024 | $31.89 Billion | $2.75 Billion | -$665.30 Million | 11.59x | N/A |
Competitor Companies of 22UA by Market Capitalization
Companies near BioNTech SE in the global market cap rankings as of May 2, 2026.
Key companies related to BioNTech SE by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
BioNTech SE Historical Marketcap From 2019 to 2026
Between 2019 and today, BioNTech SE's market cap moved from $8.95 Billion to $ 25.89 Billion, with a yearly change of 33.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €25.89 Billion | +7.95% |
| 2025 | €23.98 Billion | -24.79% |
| 2024 | €31.89 Billion | +14.42% |
| 2023 | €27.87 Billion | -34.05% |
| 2022 | €42.26 Billion | -32.69% |
| 2021 | €62.78 Billion | +194.77% |
| 2020 | €21.30 Billion | +138.03% |
| 2019 | €8.95 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of BioNTech SE was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $23.24 Billion USD |
| MoneyControl | $23.24 Billion USD |
| MarketWatch | $23.24 Billion USD |
| marketcap.company | $23.24 Billion USD |
| Reuters | $23.24 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which… Read more